%0 Journal Article
%T NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
%A Wierda WG
%A Brown J
%A Abramson JS
%A Awan F
%A Bilgrami SF
%A Bociek G
%A Brander D
%A Chanan-Khan AA
%A Coutre SE
%A Davis RS
%A Eradat H
%A Fletcher CD
%A Gaballa S
%A Ghobadi A
%A Hamid MS
%A Hernandez-Ilizaliturri F
%A Hill B
%A Kaesberg P
%A Kamdar M
%A Kaplan LD
%A Khan N
%A Kipps TJ
%A Ma S
%A Mato A
%A Mosse C
%A Schuster S
%A Siddiqi T
%A Stephens DM
%A Ujjani C
%A Wagner-Johnston N
%A Woyach JA
%A Ye JC
%A Dwyer MA
%A Sundar H
%J J Natl Compr Canc Netw
%V 20
%N 6
%D 06 2022
%M 35714675
%F 12.693
%R 10.6004/jnccn.2022.0031
%X The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.